Lung Cancer

Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.

Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.

The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.

An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 NSCLC following chemoradiotherapy.

Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, with potential severe side effects.

Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month.

Life-threatening lung cancer has taught me many valuable lessons and made my new normal so fulfilling.

Among patients with resectable non-small cell lung cancer, Opdivo plus Yervoy has displayed potential long-term clinical benefits versus chemotherapy.

The first patient with small cell lung cancer has been dosed in a trial of peluntamig (PT217) combined with chemotherapy.

After realizing that a stronger support system would have helped me emotionally and spiritually in my cancer journey, I committed myself to being there for my cousin.

Datroway demonstrated durable antitumor activity and an acceptable safety profile in advanced NSCLC with actionable genomic alterations, including EGFR and ALK subgroups.

Neoadjuvant Opdivo with platinum-doublet chemo had a statistically significant and clinically meaningful improvement versus chemo alone in resectable NSCLC.

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive results and favorable safety.

Diagnosed with early-stage lung cancer, I chose robot-assisted surgery, navigating pain, fear and the bond with fellow cancer patients through it all.

THIO sequenced with Libtayo extended overall survival in those with non–small cell lung cancer who progressed on two or more standard-of-care regimens.

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events and reduced overall survival.

Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive management of this side effect.

The first participant has been dosed on the phase 2 CONVERGE study evaluating NBTXR3 in stage III, unresectable non–small cell lung cancer.

Dr. Eric K. Singhi shares his insights into the advantages of the subcutaneous formulation of Opdivo versus the IV version for patients with solid tumors.

Following a lung cancer diagnosis, I learned that it is important to ask oncologists thoughtful questions to know if they are the best doctor for my needs.

The Lung Cancer Genetics Study, a collaboration between lung cancer advocacy organizations, aims to explore the genetics of lung cancer

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means for those with solid tumors.

From the death of a TikTok influencer to an update from a “Boy Meets World” star, here is this week’s news.

Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient access, according to experts.

The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.

The FDA has granted fast track designation for abenacianine to help surgeons better visualize lung tumors during minimally invasive surgery.

Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.

First-line Rybrevant plus Lazcluze improved survival versus the current standard of care in patients with mutated advanced or metastatic NSCLC.

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors.